2022
Rebleeding in peptic ulcer bleeding – a nationwide cohort study of 19,537 patients
Laursen S, Stanley A, Laine L, de Muckadell O. Rebleeding in peptic ulcer bleeding – a nationwide cohort study of 19,537 patients. Scandinavian Journal Of Gastroenterology 2022, 57: 1423-1429. PMID: 35853234, DOI: 10.1080/00365521.2022.2098050.Peer-Reviewed Original ResearchConceptsPeptic ulcer bleedingNationwide cohort studyUlcer bleedingHemodynamic instabilityCohort studyDuodenal ulcerHigh-risk endoscopic stigmataNon-ulcer lesionsHigh-risk stigmataLogistic regression analysisEndoscopic stigmataPersistent bleedingEndoscopic therapyFrequent complicationConsecutive patientsSuch patientsPrognostic consequencesHigh riskPatientsInterventional radiologyBleedingTwo-fold increaseMortalityUlcersStrongest predictor
2011
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS. Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. The American Journal Of Gastroenterology 2011, 107: ajg2011443. PMID: 22186979, PMCID: PMC3321505, DOI: 10.1038/ajg.2011.443.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsChi-Square DistributionDouble-Blind MethodDrug CombinationsDuodenal UlcerEndoscopy, GastrointestinalFamotidineFemaleHumansIbuprofenMaleMiddle AgedProportional Hazards ModelsRisk FactorsStomach UlcerTreatment OutcomeConceptsPrimary end point analysisNon-steroidal anti-inflammatory drugsUpper GI ulcersDuodenal ulcerGI ulcersGastric ulcerEnd-point analysisDaily non-steroidal anti-inflammatory drugsH. pylori stool testDouble-blind randomized trialsMultiple potential risk factorsReduction of gastricSingle-tablet combinationUpper gastrointestinal ulcersDouble-blind trialProportional hazards analysisPotential risk factorsAnti-inflammatory drugsBaseline endoscopyREDUCE studyStudy endoscopyTablets thriceUlcer complicationsStool testRandomized trials
2008
Intragastric pH With Oral vs Intravenous Bolus Plus Infusion Proton-Pump Inhibitor Therapy in Patients With Bleeding Ulcers
Laine L, Shah A, Bemanian S. Intragastric pH With Oral vs Intravenous Bolus Plus Infusion Proton-Pump Inhibitor Therapy in Patients With Bleeding Ulcers. Gastroenterology 2008, 134: 1836-1841. PMID: 18423628, DOI: 10.1053/j.gastro.2008.03.006.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralDrug Administration ScheduleDuodenal UlcerDuodenoscopyFemaleGastric AcidGastric Acidity DeterminationGastroscopyHumansHydrogen-Ion ConcentrationInfusions, IntravenousMaleMiddle AgedPeptic Ulcer HemorrhageProton Pump InhibitorsStomach UlcerTime FactorsTreatment OutcomeConceptsProton pump inhibitor therapyOral PPIIntravenous PPIInhibitor therapyConfidence intervalsStudy periodFrequent oral dosingHigh-risk stigmataSimilar antisecretory effectIntravenous lansoprazoleOral lansoprazolePPI therapyAntisecretory effectWide confidence intervalsIntragastric pHIntravenous bolusBleeding ulcersOral dosingPatientsBaseline pHUlcersAbstractTextTherapyAIMSBolus
2003
Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial
Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. The American Journal Of Gastroenterology 2003, 98: ajg2003137. PMID: 12650788, DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsCapsulesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDuodenal UlcerFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMiddle AgedNorth AmericaOmeprazoleOrganometallic CompoundsTetracyclineTreatment OutcomeConceptsUrea breath testQuadruple therapyDuodenal ulcerBreath testNegative urea breath testTreat eradication ratesH. pylori eradicationActive duodenal ulcerDuodenal ulcer patientsNorth American trialsClarithromycin-resistant strainsActive-controlled trialHelicobacter pylori infectionTreatment of patientsMetronidazole-resistant strainsCapsules q.OAC patientsOAC regimenEradication ratePylori eradicationTriple therapyAdverse eventsUlcer patientsPylori infectionMetronidazole resistance
2000
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials
Laine L, Fennerty M, Osato M, Sugg J, Suchower L, Probst P, Levine J. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. The American Journal Of Gastroenterology 2000, 95: ajg20001583. PMID: 11151867, DOI: 10.1111/j.1572-0241.2000.03349.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmoxicillinClarithromycinDouble-Blind MethodDrug Administration ScheduleDrug Resistance, MicrobialDrug Therapy, CombinationDuodenal UlcerEsomeprazoleFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMiddle AgedPenicillin ResistancePenicillinsProspective StudiesProtein Synthesis InhibitorsProton Pump InhibitorsConceptsEradication rateClarithromycin resistanceDaily esomeprazoleTriple therapyDuodenal ulcerProton pump inhibitor-based triple therapyTen-day triple therapyHelicobacter pylori eradication therapyEmergent resistanceH. pylori-positive patientsInhibitor-based triple therapyDouble-blind trialTreat eradication ratesCompletion of therapyPylori eradication therapyPylori-positive patientsSeparate randomized trialsAntibiotic resistanceDaily amoxicillinUS multicenterEradication therapyRandomized trialsHelicobacter pyloriTherapyEsomeprazoleComparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double‐blind, placebo‐controlled trial
Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado‐Cocco J, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumatism 2000, 43: 370-377. PMID: 10693877, DOI: 10.1002/1529-0131(200002)43:2<370::aid-anr17>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsGastroduodenal ulcersPrespecified criteriaEffect of rofecoxibPlacebo-controlled trialSecondary end pointsDouble-blind studyGastroduodenal ulcerationGastroduodenal mucosaUlcer incidenceCyclooxygenase-2Side effectsUlcersEnd pointEffective doseRofecoxibWeeksPlaceboPatientsOsteoarthritisIncidenceDoseIbuprofenUlcerationMucosaEndoscopy
1999
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J, Group F. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999, 117: 776-783. PMID: 10500058, DOI: 10.1016/s0016-5085(99)70334-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDuodenal UlcerFemaleGastric MucosaGastroscopyHumansIbuprofenIntestinal MucosaIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedOsteoarthritisProstaglandin-Endoperoxide SynthasesStomach UlcerSulfonesConceptsUlcer ratesGastroduodenal ulcersCOX-2 specific inhibitionSymptoms of osteoarthritisNonspecific COX inhibitorNormal gastrointestinal tractTreatment of patientsBaseline endoscopyGastroduodenal ulcerationPlacebo groupCumulative incidenceOsteoarthritis patientsGastroduodenal mucosaWeek 12COX inhibitorsMucosal integrityCOX-2Gastrointestinal tractInflammatory sitesProstaglandin productionDoses 2AbstractTextEffective doseUlcersPatients
1998
Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials
Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. The American Journal Of Gastroenterology 1998, 93: ajg1998488. PMID: 9820381, DOI: 10.1111/j.1572-0241.1998.00602.x.Peer-Reviewed Original ResearchConceptsDuodenal ulcer diseaseTriple therapyEradication rateUlcer diseaseH. pylori-infected patientsDaily triple therapyDays of omeprazoleDuodenal ulcer historyProtocol cure ratesProtocol eradication ratesTreat eradication ratesHelicobacter pylori eradicationPylori-infected patientsOAC patientsStudy medicationTreat populationUlcer historyPylori eradicationStudy drugAdverse eventsTwice DailyControlled TrialsDuodenal ulcerCure ratePatientsHas the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated?
Laine L, Hopkins R, Girardi L. Has the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated? The American Journal Of Gastroenterology 1998, 93: 1409. PMID: 9732917, DOI: 10.1111/j.1572-0241.1998.452_a.x.Peer-Reviewed Original ResearchConceptsH. pylori eradicationH. pylori therapyUlcer recurrencePylori eradicationPylori therapyH. pylori cureNon-NSAID ulcersCompletion of therapyHelicobacter pylori therapyUse of NSAIDsDuodenal ulcer patientsNorth American trialsUlcer recurrence rateHigh methodological qualityEndoscopic biopsy testsReview of abstractsEndoscopic followUlcer patientsDuodenal ulcerRelevant trialsRecurrence rateStudy inclusionOdds ratioCommon odds ratioMethodological qualityUS double‐blind, controlled trials of omeprazole and amoxycillin for treatment of Helicobacter pylori
Laine, Johnson, Suchower, Ronca, Hwang, Neil. US double‐blind, controlled trials of omeprazole and amoxycillin for treatment of Helicobacter pylori. Alimentary Pharmacology & Therapeutics 1998, 12: 377-382. PMID: 9690729, DOI: 10.1046/j.1365-2036.1998.00303.x.Peer-Reviewed Original ResearchConceptsH. pylori eradicationDual therapyEradication ratePylori eradicationDuodenal ulcerControlled TrialsHelicobacter pylori eradication ratesOmeprazole/amoxycillinPylori eradication ratesCompletion of therapyActive duodenal ulcerH. pylori diagnosisEndoscopic biopsy testsAmoxycillin resistanceAmoxycillin therapyAdverse eventsAmoxycillinTherapyHelicobacter pyloriOmeprazolePatientsBiopsy testsProtocol analysisUlcersTrialsAccuracy of CLOtest after Helicobacter pylori therapy
Laine L, Suchower L, Johnson E, Ronca P, Neil G. Accuracy of CLOtest after Helicobacter pylori therapy. Gastrointestinal Endoscopy 1998, 47: 250-253. PMID: 9540877, DOI: 10.1016/s0016-5107(98)70321-9.Peer-Reviewed Original ResearchConceptsHelicobacter pylori therapyPylori therapyOmeprazole/amoxicillinCompletion of therapyDouble-blind trialRapid urease testingMore effective therapiesEndoscopic biopsy testsOmeprazole therapyAdditional therapyMost patientsDual therapyUnsuccessful treatmentUrease testingEffective therapyPositive testPatientsH. pyloriTherapyCLOtestBiopsy testsDecreased numberWeeksNegative resultsAmoxicillin
1996
Helicobacter pylori and Complicated Ulcer Disease
Laine L. Helicobacter pylori and Complicated Ulcer Disease. The American Journal Of Medicine 1996, 100: 52s-59s. PMID: 8644783, DOI: 10.1016/s0002-9343(96)80229-4.Peer-Reviewed Original ResearchConceptsMaintenance antisecretory therapyComplicated ulcer diseaseUlcer diseaseAntisecretory therapyEradication therapyHelicobacter pyloriH. pylori eradication therapyH. pylori infection statusPylori eradication therapyMajority of patientsPeptic ulcer diseaseEnd of therapyPylori infection statusPrevalence of infectionComplicated ulcersUncomplicated ulcersRecurrent bleedingUlcer healingPatientsTherapyInfection statusUlcersDiseaseBleedingOne-third